339 related articles for article (PubMed ID: 29623210)
1. New-onset insulin-dependent diabetes due to nivolumab.
Zaied AA; Akturk HK; Joseph RW; Lee AS
Endocrinol Diabetes Metab Case Rep; 2018; 2018():. PubMed ID: 29623210
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
[TBL] [Abstract][Full Text] [Related]
3. Diabetic Ketoacidosis as a Delayed Immune-Related Event after Discontinuation of Nivolumab.
Mae S; Kuriyama A; Tachibana H
J Emerg Med; 2021 Mar; 60(3):342-344. PubMed ID: 33097350
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab-induced fulminant type 1 diabetes with C-peptide persistence at first referral.
Kusuki K; Suzuki S; Mizuno Y
Endocrinol Diabetes Metab Case Rep; 2020 Apr; 2020():. PubMed ID: 32478673
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic mucosal melanoma.
Goff CB; Plaxe SC; White W; Dasanu CA
J Oncol Pharm Pract; 2023 Jul; 29(5):1259-1263. PubMed ID: 36734125
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event.
Yilmaz M
J Oncol Pharm Pract; 2020 Jan; 26(1):236-239. PubMed ID: 30955467
[TBL] [Abstract][Full Text] [Related]
7. Hyperosmolar Hyperglycaemic State and Diabetic Ketoacidosis in Nivolumab-Induced Insulin-Dependent Diabetes Mellitus.
Saleh AO; Taha R; Mohamed SFA; Bashir M
Eur J Case Rep Intern Med; 2021; 8(8):002756. PubMed ID: 34527623
[TBL] [Abstract][Full Text] [Related]
8. Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism.
Patel S; Chin V; Greenfield JR
Endocrinol Diabetes Metab Case Rep; 2019 Dec; 2019():. PubMed ID: 31829972
[TBL] [Abstract][Full Text] [Related]
9. A Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma.
Wu L; Li B
Diabetes Metab Syndr Obes; 2021; 14():753-757. PubMed ID: 33628041
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes.
Miyoshi Y; Ogawa O; Oyama Y
Tohoku J Exp Med; 2016 Jun; 239(2):155-8. PubMed ID: 27297738
[TBL] [Abstract][Full Text] [Related]
11. A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma.
Hakami OA; Ioana J; Ahmad S; Tun TK; Sreenan S; McDermott JH
Endocrinol Diabetes Metab Case Rep; 2019 Mar; 2019():. PubMed ID: 30836329
[TBL] [Abstract][Full Text] [Related]
12. Rapid-onset diabetic ketoacidosis secondary to nivolumab therapy.
Lee S; Morgan A; Shah S; Ebeling PR
Endocrinol Diabetes Metab Case Rep; 2018; 2018():. PubMed ID: 29732161
[TBL] [Abstract][Full Text] [Related]
13. Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases.
Lupi I; Brancatella A; Cosottini M; Viola N; Lanzolla G; Sgrò D; Dalmazi GD; Latrofa F; Caturegli P; Marcocci C
Endocrinol Diabetes Metab Case Rep; 2019 Oct; 2019():. PubMed ID: 31610523
[TBL] [Abstract][Full Text] [Related]
14. Fulminant onset of insulin-dependent diabetes with positive anti-GAD antibody titers during treatment with nivolumab in a patient with NSCLC.
Matsuura N; Koh G; Konishi C; Minamino S; Takahara Y; Harada H; Kodama K; Emoto M
Cancer Immunol Immunother; 2018 Sep; 67(9):1417-1424. PubMed ID: 29995236
[TBL] [Abstract][Full Text] [Related]
15. Ketosis-prone diabetes and SLE co-presenting in an African lady with previous gestational diabetes.
Hussain S; Keat S; Gelding SV
Endocrinol Diabetes Metab Case Rep; 2017; 2017():. PubMed ID: 29026609
[TBL] [Abstract][Full Text] [Related]
16. New-onset type 1 diabetes mellitus as a delayed immune-related event after discontinuation of nivolumab: A case report.
Seo JH; Lim T; Ham A; Kim YA; Lee M
Medicine (Baltimore); 2022 Sep; 101(35):e30456. PubMed ID: 36107574
[TBL] [Abstract][Full Text] [Related]
17. Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab.
Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2018 Jan; 244(1):33-40. PubMed ID: 29343652
[TBL] [Abstract][Full Text] [Related]
18. Prolonged acidosis is a feature of SGLT2i-induced euglycaemic diabetic ketoacidosis.
Rafey MF; Butt A; Coffey B; Reddington L; Devitt A; Lappin D; Finucane FM
Endocrinol Diabetes Metab Case Rep; 2019 Sep; 2019():. PubMed ID: 31600728
[TBL] [Abstract][Full Text] [Related]
19. A Rare Case of Severe Diabetic Ketoacidosis in a Patient With Metastatic Renal Cell Carcinoma Being Treated With Nivolumab.
Bazzi T; Gupta E; Mohamed A; Vashi M
Cureus; 2022 Sep; 14(9):e29537. PubMed ID: 36312693
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous onset of type 1 diabetes mellitus and silent thyroiditis under durvalumab treatment.
Mengíbar JL; Capel I; Bonfill T; Mazarico I; Espuña LC; Caixàs A; Rigla M
Endocrinol Diabetes Metab Case Rep; 2019 Jul; 2019(1):. PubMed ID: 31310083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
